NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-NR-23-003 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-036 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission.
Funding Opportunity PAR-23-037 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice NOT-HD-19-034: To enhance the rigor and reproducibility of clinical trial protocols To promote greater availability of multisite clinical trial infrastructure to support trials from a wider range of investigators To facilitate data sharing and access to biospecimens to efficiently expand research capacity for all investigators To facilitate greater involvement of diverse populations in multisite clinical trials. Consequently, multisite clinical trials and observational studies conducted by and within the participating NICHD-supported Clinical Research Networks will be submitted as investigator-initiated, multi-Principal Investigator (PI) grant applications by any qualified investigator in the extramural community (including NICHD Network investigators) in conjunction with the respective NICHD Network Data Coordinating Center (DCC). It is the intent of this initiative to utilize the NICHD Clinical Research Network infrastructure in a manner that will promote the funding and support of the best science in a timely, transparent, equitable and cost-effective manner.
Funding Opportunity RFA-DK-22-027 from the NIH Guide for Grants and Contracts. The overall goal of the Fostering Research with Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the urology (excluding cancer) research community. The objective of each FORWARD Urology Center will be to support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising primarily of junior investigators with at least one Early Stage Investigator (ESI) and/or researcher new to urology. Research Project data are expected to support one or more follow-on independent grant applications (e.g., R01s) submitted by Research Project Team investigators. The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Project Team to help ensure the research aims are met and to aid them in their successful integration into the broader urologic research field. The Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDKs CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program.
Notice NOT-OD-23-030 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-023 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-OD-23-002 from the NIH Guide for Grants and Contracts. This FOA announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIHs mission. Funded Hubs are intended to work as a consortium to enable: (1) the infrastructure for identifying the most promising technologies, (2) funding for product definition studies (e.g. feasibility studies, prototype development, proof-of-concept studies) provided to individual researchers, (3) access to resources and expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and (4) skills development and hands-on experience in entrepreneurship. Establishing public-private partnerships and providing additional non-federal funds will be critical for success.
Notice NOT-AI-23-013 from the NIH Guide for Grants and Contracts
Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)
Funding Opportunity RFA-RM-23-003 from the NIH Guide for Grants and Contracts. Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund data sets, including generating hypotheses and catalyzing discoveries. Award recipients are also asked to provide feedback on the utility of the Common Fund data resources.
Notice NOT-NS-23-045 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-044 from the NIH Guide for Grants and Contracts
Notice NOT-AI-23-009 from the NIH Guide for Grants and Contracts
Notice NOT-AI-23-007 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-017 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-014 from the NIH Guide for Grants and Contracts
Notice NOT-AI-23-012 from the NIH Guide for Grants and Contracts
Notice NOT-AI-23-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-256 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions to improve health equity and reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Funding Opportunity PAR-23-038 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support Testing Centers for Somatic Cell Genome Editing in specified major mammalian animal model species (rodents, pigs, and non-human primates). Each Center will provide resources and testing services to the growing community developing new genome editing technologies and conducting preclinical testing based upon these technologies for therapeutics of human diseases. The Testing Centers will work with NIH funded investigators to assess the efficacy and safety of in vivo genome editing and delivery technologies, determine genome editing thresholds for specific diseases associated with minimal off-target effects, and ascertain feasibility parameters in a model system. This data will be important in determining if a treatment strategy using a specific set of tools is effective and has an acceptable safety profile, or if the efficacy and specificity of editing should be significantly improved. Even though each Testing Center will work on a limited number of focused projects, it is expected that the program and pipeline(s) developed will maintain multifaceted research activities to build core model systems that can be adjusted as required to accommodate a broad spectrum of diseases as well as provide fee-for-service to the wider biomedical community on a national basis.
Funding Opportunity PAR-23-065 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.